• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Adona Medical completes enrollment in first-in-human interatrial shunt trial

Adona Medical completes enrollment in first-in-human interatrial shunt trial

June 17, 2025 By Sean Whooley

This is an Adona Medical marketing image of its novel interatrial shunt with integrated bi-atrial pressure monitoring.
Adona Medical is developing what it describes as a novel interatrial shunt with integrated bi-atrial pressure monitoring. [Image courtesy of Adona Medical.

Shifamed‘s Adona Medical announced today that it completed enrollment in the ATHENS-HF first-in-human study of its interatrial shunt.

The company initiated the study last year, announcing the successful first-in-human use of the novel shunt in patients with heart failure in October.

Adona Medical utilizes nitinol’s shape memory properties in an adjustable, bi-atrial-sensing heart device. The device features a shunt with a flow channel that offers an adaptable geometry capable of growing larger or minimizing at any time post-implant. This can help optimize shunting flow or dose for patient needs at the time of the initial procedure. It can then adjust as the patient’s condition evolves over time to provide tailored hemodynamic modulation.

Los Gatos, California-based Adona integrated sensors into the shunt to capture pressure readings from both the left and right atria multiple times per day without requiring patient interaction. These readings deliver a more complete picture of a patient’s hemodynamic status.

Nitinol innovation: Download our free special report featuring coverage of Adona Medical and other medical device OEMs

Update on the Adona Medical trial

Today, the company says investigators successfully implanted the shunt in 10 patients with heart failure with 100% procedural success. All patients had their shunt diameters successfully adapted, both larger and smaller relative to an initial configuration.

ATHENS-HF enrolled patients with both preserved and reduced ejection fraction heart failure. Adona said the majority of patients reached the 90-day follow-up timepoint after the original procedure. As planned, they underwent additional treatments to alter the shunt size several months after the initial implantation.

Adona reports no major pocedural complications or site-reported major adverse cardiovascular and neurovascular events (MACNE) in the entire cohort to date.

“Completing enrollment in our first-in-human study ahead of schedule marks a pivotal milestone that highlights our team’s ability to execute upon our ambitious mission,” stated Brian Fahey, co-founder and CEO of Adona Medical. “The strong early results are a clear indicator that we’re building a platform that has the potential to transform heart failure management. We are well-positioned for our next phases, with a plan to advance our clinical program with the evaluation of next-generation devices later this year.”

Filed Under: Cardiac Implants, Cardiovascular, Clinical Trials, Implants, Structural Heart Tagged With: Adona Medical, nitinol, Nitinol Devices & Components

More recent news

  • NICE recommends Boston Scientific Farapulse pulsed field ablation tech
  • SS Innovations completes first robotic telesurgery for weight loss
  • Johnson & Johnson MedTech adds new CMO for its Electrophysiology business
  • Abbott earns Medicare win for TriClip TEER system
  • Judge says Johnson & Johnson Ethicon owes $76.6M to ChemImage after failed partnership

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy